<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37515027</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Assessment of Enterovirus Excretion and Identification of VDPVs in Patients with Primary Immunodeficiency in India: Outcome of ICMR-WHO Collaborative Study Phase-I.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1211</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines11071211</ELocationID><Abstract><AbstractText>The emergence of vaccine-derived polioviruses (VDPVs) in patients with Primary Immunodeficiency (PID) is a threat to the polio-eradication program. In a first of its kind pilot study for successful screening and identification of VDPV excretion among patients with PID in India, enteroviruses were assessed in stool specimens of 154 PID patients across India in a period of two years. A total of 21.42% of patients were tested positive for enteroviruses, 2.59% tested positive for polioviruses (PV), whereas 18.83% of patients were positive for non-polio enteroviruses (NPEV). A male child of 3 years and 6 months of age diagnosed with Hyper IgM syndrome was detected positive for type1 VDPV (iVDPV1) with 1.6% nucleotide divergence from the parent Sabin strain. E21 (19.4%), E14 (9%), E11 (9%), E16 (7.5%), and CVA2 (7.5%) were the five most frequently observed NPEV types in PID patients. Patients with combined immunodeficiency were at a higher risk for enterovirus infection as compared to antibody deficiency. The high susceptibility of PID patients to enterovirus infection emphasizes the need for enhanced surveillance of these patients until the use of OPV is stopped. The expansion of PID surveillance and integration with a national program will facilitate early detection and follow-up of iVDPV excretion to mitigate the risk for iVDPV spread.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohanty</LastName><ForeName>Madhu Chhanda</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-6942-2875</Identifier><AffiliationInfo><Affiliation>Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Mukesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, Bai Jerbai Wadia Hospital for Children, Mumbai 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammad</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>World Health Organization, Country Office, New Delhi 110011, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Amita</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2187-5186</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology &amp; Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Govindaraj</LastName><ForeName>Geeta</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3450-455X</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Government Medical College, Kozhikode 673008, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattad</LastName><ForeName>Sagar</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5048-9727</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Aster CMI Hospital, Bangalore 560092, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashkari</LastName><ForeName>Harsha Prasada</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kasturba Medical College, Mangalore 576104, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajasekhar</LastName><ForeName>Liza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad 500082, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Harish</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>World Health Organization, CH-1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Arun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>World Health Organization, Country Office, New Delhi 110011, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawant</LastName><ForeName>Unnati</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varose</LastName><ForeName>Swapnil Yashwant</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taur</LastName><ForeName>Prasad</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Immunology, Bai Jerbai Wadia Hospital for Children, Mumbai 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Reetika Malik</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Immunohaematology (ICMR-NIIH), Mumbai 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatkare</LastName><ForeName>Manogat</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2599-6073</Identifier><AffiliationInfo><Affiliation>Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Mevis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bargir</LastName><ForeName>Umair</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Immunohaematology (ICMR-NIIH), Mumbai 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majumdar</LastName><ForeName>Sanjukta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology &amp; Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edavazhippurath</LastName><ForeName>Athulya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Multidisciplinary Research Unit, Government Medical College, Kozhikode 673008, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rangarajan</LastName><ForeName>Jyoti</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Aster CMI Hospital, Bangalore 560092, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manthri</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad 500082, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madkaikar</LastName><ForeName>Manisha Ranjan</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Immunohaematology (ICMR-NIIH), Mumbai 400012, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AFP surveillance</Keyword><Keyword MajorTopicYN="N">Global Polio Eradication Initiative (GPEI)</Keyword><Keyword MajorTopicYN="N">Oral Polio Vaccine (OPV)</Keyword><Keyword MajorTopicYN="N">combined immunodeficiency (CID)</Keyword><Keyword MajorTopicYN="N">enteroviruses</Keyword><Keyword MajorTopicYN="N">iVDPV surveillance</Keyword><Keyword MajorTopicYN="N">immunodeficiency-related vaccine-derived polioviruses (iVDPV)</Keyword><Keyword MajorTopicYN="N">inborn errors of immunity (IEI)</Keyword><Keyword MajorTopicYN="N">polio eradication</Keyword><Keyword MajorTopicYN="N">primary immunodeficiency disorder (PID)</Keyword><Keyword MajorTopicYN="N">prolonged excretion</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37515027</ArticleId><ArticleId IdType="pmc">PMC10383878</ArticleId><ArticleId IdType="doi">10.3390/vaccines11071211</ArticleId><ArticleId IdType="pii">vaccines11071211</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bigouette J.P., Wilkinson A.L., Tallis G., Burns C.C., Wassilak S.G.F., Vertefeuille J.F. Progress toward Polio Eradication—Worldwide, January 2019–June 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1129–1135. doi: 10.15585/mmwr.mm7034a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7034a1</ArticleId><ArticleId IdType="pmc">PMC8389387</ArticleId><ArticleId IdType="pubmed">34437527</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Detection of Circulating Vaccine Derived Polio Virus 2 (cVDPV2) in Environmental Samples—The United Kingdom of Great Britain and Northern Ireland and the United States of America.  [(accessed on 20 January 2023)].  Available online:  https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON408.</Citation></Reference><Reference><Citation>Guo J., Bolivar-Wagers S., Srinivas N., Holubar M., Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: A systematic review and implications for polio eradication. Vaccine. 2015;33:1235–1242. doi: 10.1016/j.vaccine.2015.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.01.018</ArticleId><ArticleId IdType="pmc">PMC5529169</ArticleId><ArticleId IdType="pubmed">25600519</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G., Diop O.M., Humayun A., Shahmahmoodi S., El-Sayed Z.A., Triki H., Rey G., Avagyan T., Grabovac V., Jorba J., et al. Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses—Worldwide, July 2018–December 2019. MMWR Morb. Mortal. Wkly. Rep. 2020;69:913–917. doi: 10.15585/mmwr.mm6928a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6928a4</ArticleId><ArticleId IdType="pmc">PMC7366852</ArticleId><ArticleId IdType="pubmed">32673297</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangye S.G., Al-Herz W., Bousfiha A., Cunningham-Rundles C., Franco J.L., Holland S.M., Klein C., Morio T., Oksenhendler E., Picard C., et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J. Clin. Immunol. 2022;42:1473–1507. doi: 10.1007/s10875-022-01289-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01289-3</ArticleId><ArticleId IdType="pmc">PMC9244088</ArticleId><ArticleId IdType="pubmed">35748970</ArticleId></ArticleIdList></Reference><Reference><Citation>Galal N.M., Meshaal S., ElHawary R., Nasr E., Bassiouni L., Ashghar H., Farag N.H., Mach O., Burns C., Iber J., et al. Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: Clinicians’ perspectives in the endgame plan for polio eradication. BMC Res. Notes. 2018;11:717. doi: 10.1186/s13104-018-3822-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-018-3822-7</ArticleId><ArticleId IdType="pmc">PMC6180599</ArticleId><ArticleId IdType="pubmed">30305145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao N., Liu Y., Xu J.-W., Wang Q., Yin Z.-D., Wen N., Yang H., Rodewald L.E., Zhang Z.-Y. Detection of a Highly Divergent Type 3 Vaccine-Derived Poliovirus in a Child with a Severe Primary Immunodeficiency Disorder—Chongqing, China, 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:1148–1150. doi: 10.15585/mmwr.mm7136a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7136a2</ArticleId><ArticleId IdType="pmc">PMC9470223</ArticleId><ArticleId IdType="pubmed">36074738</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G., Liao Y., Takane M., Dooling K., Gilmour S., Mach O., Kew O.M., Sutter R.W., The iVDPV Working Group. Diop O., et al. Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry. Front. Immunol. 2017;8:1103. doi: 10.3389/fimmu.2017.01103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01103</ArticleId><ArticleId IdType="pmc">PMC5622164</ArticleId><ArticleId IdType="pubmed">28993765</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty M.C., Madkaikar M.R., Desai M., Taur P., Nalavade U.P., Sharma D.K., Gupta M., Dalvi A., Shabrish S., Kulkarni M., et al. Poliovirus Excretion in Children with Primary Immunodeficiency Disorders, India. Emerg. Infect. Dis. 2017;23:1664–1670. doi: 10.3201/eid2310.170724.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2310.170724</ArticleId><ArticleId IdType="pmc">PMC5621533</ArticleId><ArticleId IdType="pubmed">28930011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lickness J.S., Gardner T., Diop O.M., Chavan S., Jorba J., Ahmed J., Gumede N., Johnson T., Butt O., Asghar H., et al. Surveillance to Track Progress toward Polio Eradication—Worldwide, 2018–2019. MMWR Morb. Mortal. Wkly. Rep. 2020;69:623–629. doi: 10.15585/mmwr.mm6920a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6920a3</ArticleId><ArticleId IdType="pubmed">32437342</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Polio Laboratory Manual. 4th ed. WHO; Geneva, Switzerland: 2004.</Citation></Reference><Reference><Citation>Weldon W.C., Oberste M.S., Pallansch M.A. Standardized Methods for Detection of Poliovirus Antibodies. Methods Mol. Biol. 2016;1387:145–176. doi: 10.1007/978-1-4939-3292-4_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3292-4_8</ArticleId><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffett D.B., Llewellyn A., Singh H., Saxentoff E., Partridge J., Boualam L., Pallansch M., Wassilak S., Asghar H., Roesel S., et al. Progress toward Poliovirus Containment Implementation—Worldwide, 2019–2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:1330–1333. doi: 10.15585/mmwr.mm6937a7.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6937a7</ArticleId><ArticleId IdType="pmc">PMC7498175</ArticleId><ArticleId IdType="pubmed">32941411</ArticleId></ArticleIdList></Reference><Reference><Citation>Team W. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2019: Conclusions and Recommendations. Wkly. Epidemiol. Rec. 2019;94:261–279.</Citation><ArticleIdList><ArticleId IdType="pubmed">26027016</ArticleId></ArticleIdList></Reference><Reference><Citation>Inactivated Polio Vaccine Now Introduced Worldwide.  [(accessed on 20 January 2023)].  Available online:  https://polioeradication.org/news-post/inactivated-polio-vaccine-now-introduced-worldwide/</Citation></Reference><Reference><Citation>Aghamohammadi A., Abolhassani H., Kutukculer N., Wassilak S.G., Pallansch M.A., Kluglein S., Quinn J., Sutter R.W., Wang X., Sanal O., et al. Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication. Front. Immunol. 2017;8:685. doi: 10.3389/fimmu.2017.00685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00685</ArticleId><ArticleId IdType="pmc">PMC5468416</ArticleId><ArticleId IdType="pubmed">28952612</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty M.C., Madkaikar M.R., Desai M., Aluri J., Varose S.Y., Taur P., Sharma D.K., Nalavade U.P., Rane S.V., Gupta M., et al. Natural Clearance of Prolonged VDPV Infection in a Child with Primary Immunodeficiency Disorder. Front. Immunol. 2019;10:1567. doi: 10.3389/fimmu.2019.01567.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01567</ArticleId><ArticleId IdType="pmc">PMC6663979</ArticleId><ArticleId IdType="pubmed">31396204</ArticleId></ArticleIdList></Reference><Reference><Citation>França T.T., Barreiros L.A., Al-Ramadi B.K., Ochs H.D., Cabral-Marques O., Condino-Neto A. CD40 ligand deficiency: Treatment strategies and novel therapeutic perspectives. Expert Rev. Clin. Immunol. 2019;15:529–540. doi: 10.1080/1744666X.2019.1573674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2019.1573674</ArticleId><ArticleId IdType="pubmed">30681380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lougaris V., Badolato R., Ferrari S., Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: Clinical, molecular, and immunological features. Immunol. Rev. 2005;203:48–66. doi: 10.1111/j.0105-2896.2005.00229.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0105-2896.2005.00229.x</ArticleId><ArticleId IdType="pubmed">15661021</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J., Van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Genet. 2018;16:368–381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyrdak R., Grabbe M., Hammas B., Ekwall J., E Hansson K., Luthander J., Naucler P., Reinius H., Rotzén-Östlund M., Albert J. Outbreak of enterovirus D68 of the new B3 lineage in Stockholm, Sweden, August to September 2016. Eurosurveillance. 2016;21:30403. doi: 10.2807/1560-7917.ES.2016.21.46.30403.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.46.30403</ArticleId><ArticleId IdType="pmc">PMC5144949</ArticleId><ArticleId IdType="pubmed">27918255</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogka V., Labropoulou S., Emmanouil M., Voulgari-Kokota A., Vernardaki A., Georgakopoulou T., Mentis A.F. Laboratory Surveillance of Polio and Other Enteroviruses in High-Risk Populations and Environmental Samples. Appl. Environ. Microbiol. 2017;83:e02872-16. doi: 10.1128/AEM.02872-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.02872-16</ArticleId><ArticleId IdType="pmc">PMC5311404</ArticleId><ArticleId IdType="pubmed">28039136</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Garcia M.D., Kebe O., Fall A.D., Ndiaye K. Identification and molecular characterization of non-polio enteroviruses from children with acute flaccid paralysis in West Africa, 2013–2014. Sci. Rep. 2017;7:3808. doi: 10.1038/s41598-017-03835-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-03835-1</ArticleId><ArticleId IdType="pmc">PMC5476622</ArticleId><ArticleId IdType="pubmed">28630462</ArticleId></ArticleIdList></Reference><Reference><Citation>Benschop K.S.M., van der Avoort H.G., Jusic E., Vennema H., van Binnendijk R., Duizer E. Polio and Measles Down the Drain: Environmental Enterovirus Surveillance in the Netherlands, 2005 to 2015. Appl. Environ. Microbiol. 2017;83:e00558-17. doi: 10.1128/AEM.00558-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00558-17</ArticleId><ArticleId IdType="pmc">PMC5478994</ArticleId><ArticleId IdType="pubmed">28432101</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar M., Sharif S., Klapsa D., Wilton T., Alam M.M., Garcia M.D.F., Rehman L., Mujtaba G., McAllister G., Harvala H., et al. Environmental Surveillance Reveals Complex Enterovirus Circulation Patterns in Human Populations. Open Forum Infect. Dis. 2018;5:ofy250. doi: 10.1093/ofid/ofy250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofy250</ArticleId><ArticleId IdType="pmc">PMC6201154</ArticleId><ArticleId IdType="pubmed">30377626</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer T.K., Simmonds P., Harvala H. The importance of enterovirus surveillance in a post-polio world. Lancet Infect. Dis. 2022;22:e35–e40. doi: 10.1016/S1473-3099(20)30852-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30852-5</ArticleId><ArticleId IdType="pubmed">34265258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouikha A., Rezig D., Driss N., Abdelkhalek I., Ben Yahia A., Touzi H., Meddeb Z., Ben Farhat E., Yahyaoui M., Triki H. Circulation and Molecular Epidemiology of Enteroviruses in Paralyzed, Immunodeficient and Healthy Individuals in Tunisia, a Country with a Polio-Free Status for Decades. Viruses. 2021;13:380. doi: 10.3390/v13030380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030380</ArticleId><ArticleId IdType="pmc">PMC7997211</ArticleId><ArticleId IdType="pubmed">33673590</ArticleId></ArticleIdList></Reference><Reference><Citation>Razafindratsimandresy R., Joffret M.-L., Andriamandimby S.F., Andriamamonjy S., Rabemanantsoa S., Richard V., Delpeyroux F., Heraud J.-M., Bessaud M. Enterovirus detection in different regions of Madagascar reveals a higher abundance of enteroviruses of species C in areas where several outbreaks of vaccine-derived polioviruses occurred. BMC Infect. Dis. 2022;22:821. doi: 10.1186/s12879-022-07826-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07826-0</ArticleId><ArticleId IdType="pmc">PMC9641760</ArticleId><ArticleId IdType="pubmed">36348312</ArticleId></ArticleIdList></Reference><Reference><Citation>Laassri M., Zagorodnyaya T., Hassin-Baer S., Handsher R., Sofer D., Weil M., Karagiannis K., Simonyan V., Chumakov K., Shulman L. Evolution of echovirus 11 in a chronically infected immunodeficient patient. PLoS Pathog. 2018;14:e1006943. doi: 10.1371/journal.ppat.1006943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006943</ArticleId><ArticleId IdType="pmc">PMC5875893</ArticleId><ArticleId IdType="pubmed">29554133</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora R., Kaplan M., Nelson M. Enterovirus-specific IgG in intravenous immunoglobulin preparations. Ann. Allergy Asthma Immunol. 2011;106:544–545. doi: 10.1016/j.anai.2011.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2011.03.007</ArticleId><ArticleId IdType="pubmed">21624761</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Carvalho B.T., Sullivan K.E., Fontes P.M., Aimé-Nobre F., Gonzales I.G.S., Lima E.S., Granato C., de Moraes-Pinto M.I. Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment. J. Clin. Immunol. 2018;38:628–634. doi: 10.1007/s10875-018-0531-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-018-0531-x</ArticleId><ArticleId IdType="pubmed">30006913</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanaroff A.A., Korones S.B., Wright L.L., Wright E.C., Poland R.L., Bauer C.B., Tyson J.E., Philips J.B., Edwards W., Lucey J.F., et al. A Controlled Trial of Intravenous Immune Globulin to Reduce Nosocomial Infections in Very-Low-Birth-Weight Infants. N. Engl. J. Med. 1994;330:1107–1113. doi: 10.1056/NEJM199404213301602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199404213301602</ArticleId><ArticleId IdType="pubmed">8133853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sazzad H.M.S., Rainey J.J., Kahn A.-L., Mach O., Liyanage J.B.L., Alam A.N., Kawser C.A., Hossain A., Sutter R., Luby S. Screening for Long-term Poliovirus Excretion Among Children with Primary Immunodeficiency Disorders: Preparation for the Polio Posteradication Era in Bangladesh. J. Infect. Dis. 2014;210((Suppl. S1)):S373–S379. doi: 10.1093/infdis/jiu221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu221</ArticleId><ArticleId IdType="pubmed">25316858</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>